Stay updated on Biomarker Study in Melanoma: Nivolumab + Ipilimumab Clinical Trial
Sign up to get notified when there's something new on the Biomarker Study in Melanoma: Nivolumab + Ipilimumab Clinical Trial page.

Latest updates to the Biomarker Study in Melanoma: Nivolumab + Ipilimumab Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThe page now shows Revision: v3.3.4 and no longer shows v3.3.3, reflecting a minor revision update. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check15 days agoNo Change Detected
- Check30 days agoChange DetectedA centralized Locations section now lists District of Columbia, Florida, New Jersey, and New York as study sites, replacing separate location subsections and removing the HHS Vulnerability Disclosure link.SummaryDifference0.5%

- Check58 days agoChange DetectedRevision updated from v3.2.0 to v3.3.2; no study content or eligibility details were affected. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check65 days agoChange DetectedThe government funding notice banner on the page has been removed. The study details and navigation remain unchanged.SummaryDifference0.4%

- Check80 days agoChange DetectedResults-related information has been added to the Study Record Dates, including a newly posted results entry dated 2024-04-04 and related QC updates. The page now reflects posted results and completed study record updates.SummaryDifference0.4%

- Check108 days agoChange Detected- Added a government-operating-status notice and a link to official sources, indicating the page may have dynamic status information. - Updated version from v3.1.0 to v3.2.0, signaling a new release.SummaryDifference4%

Stay in the know with updates to Biomarker Study in Melanoma: Nivolumab + Ipilimumab Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Biomarker Study in Melanoma: Nivolumab + Ipilimumab Clinical Trial page.